$18 Million Diabetes Supply Company located in the Southwest.
Business Description
$18 Million Diabetes Supply Company located in the Southwest.
Ensure Care Capital is proud to exclusively present a well-established Diabetic Supply Company located in the Southwest, specializing in Diabetic Supplies, Continuous Glucose Monitoring (CGM), and Urinary Catheters. Founded in 2015, the company has experienced consistent, year-over-year growth and has become a respected leader in the direct-to-patient medical supply industry.
The company is licensed by Medicare (CMS) and accredited by the Board of Certification (BOC), with a payer mix of 80% Medicare and 20% private insurance. It operates under strict HIPAA compliance, ensuring the highest standards of privacy and quality in every aspect of patient care and service delivery.
The true value of this business lies in its over 5,000 CGM clients, a number that continues to grow steadily each week.
A Strategic buyer will add 5,000 new CGM clients to their existing business at closing.
With a strong emphasis on direct-to-consumer services, the company has refined its shipping model to be cost-effective, dependable, and user-friendly. Customers benefit from timely home delivery, simplified product codes, and color-coded labeling, enabling quick and efficient inventory tracking. These features save valuable time for caregivers, allowing them to focus on providing high-quality clinical care.
The organization is staffed by a team of experienced professionals dedicated to compassionate, patient-centered care. Services emphasize preventive care, diagnosis, and treatment, with the overarching goal of improving the health and quality of life for the patients and communities it serves. The company also supports caregivers and practitioners through its customer-focused solutions, including offerings tailored to the diabetes segment, helping providers meet and maintain lofty standards of care.
Over the years, the business has built a loyal and growing customer base. One of its most significant assets is its rapidly expanding Continuous Glucose Monitoring (CGM) program, which currently serves over 5,000 active clients, with new enrollments occurring weekly. This core CGM client base represents a key value driver for a strategic buyer.
The company is recession-resistant and presents substantial growth opportunities, particularly with expansion into the East Coast and Southeast regions, where demand for its services is expected to be strong. A strategic buyer with additional sales and marketing resources could significantly accelerate top-line revenue growth.
The current owner is committed to supporting a smooth transition and is willing to remain with the business for up to one-year post-sale, making this an ideal acquisition for a strategic buyer seeking to expand in the healthcare supply space.
In 2022 they had Gross Revenue of $17.24 Million with EBITDA of $719,800. In 2023 Gross Revenue of $22,89 Million with EBITDA of $1.06 Million. In 2024 Gross Revenue was $18.06 Million with EBITDA of $565,000. In 2025 They are on track for $17 Million with EBITDA in the $700.000 range
The asking price is Negotiable.
Ensure Care Capital is proud to exclusively present a well-established Diabetic Supply Company located in the Southwest, specializing in Diabetic Supplies, Continuous Glucose Monitoring (CGM), and Urinary Catheters. Founded in 2015, the company has experienced consistent, year-over-year growth and has become a respected leader in the direct-to-patient medical supply industry.
The company is licensed by Medicare (CMS) and accredited by the Board of Certification (BOC), with a payer mix of 80% Medicare and 20% private insurance. It operates under strict HIPAA compliance, ensuring the highest standards of privacy and quality in every aspect of patient care and service delivery.
The true value of this business lies in its over 5,000 CGM clients, a number that continues to grow steadily each week.
A Strategic buyer will add 5,000 new CGM clients to their existing business at closing.
With a strong emphasis on direct-to-consumer services, the company has refined its shipping model to be cost-effective, dependable, and user-friendly. Customers benefit from timely home delivery, simplified product codes, and color-coded labeling, enabling quick and efficient inventory tracking. These features save valuable time for caregivers, allowing them to focus on providing high-quality clinical care.
The organization is staffed by a team of experienced professionals dedicated to compassionate, patient-centered care. Services emphasize preventive care, diagnosis, and treatment, with the overarching goal of improving the health and quality of life for the patients and communities it serves. The company also supports caregivers and practitioners through its customer-focused solutions, including offerings tailored to the diabetes segment, helping providers meet and maintain lofty standards of care.
Over the years, the business has built a loyal and growing customer base. One of its most significant assets is its rapidly expanding Continuous Glucose Monitoring (CGM) program, which currently serves over 5,000 active clients, with new enrollments occurring weekly. This core CGM client base represents a key value driver for a strategic buyer.
The company is recession-resistant and presents substantial growth opportunities, particularly with expansion into the East Coast and Southeast regions, where demand for its services is expected to be strong. A strategic buyer with additional sales and marketing resources could significantly accelerate top-line revenue growth.
The current owner is committed to supporting a smooth transition and is willing to remain with the business for up to one-year post-sale, making this an ideal acquisition for a strategic buyer seeking to expand in the healthcare supply space.
In 2022 they had Gross Revenue of $17.24 Million with EBITDA of $719,800. In 2023 Gross Revenue of $22,89 Million with EBITDA of $1.06 Million. In 2024 Gross Revenue was $18.06 Million with EBITDA of $565,000. In 2025 They are on track for $17 Million with EBITDA in the $700.000 range
The asking price is Negotiable.
About the Business
- Years in Operation
- 10
- Number of Employees
- 11
- Opportunities for Growth
- Market Growth Drivers:
• Increasing Prevalence of Diabetes: The rising number of people with diabetes, particularly in low- and middle-income countries, is driving demand for CGM devices. According to the International Diabetes Federation, 537 million adults lived with diabetes in 2021, and this number is expected to increase to 642 million by 2040.
• Aging Population: As the geriatric population grows, the demand for CGM devices is increasing, especially among elderly individuals who may struggle to monitor their blood glucose levels frequently.
About the Sale
- Seller Motivation
- Other Business Interests
Listing Info
- ID
- 2383496
- Listing Views
- 802
Listing ID: 2383496 The information on this listing has been provided by either the seller or a business broker representing the seller. BizQuest has no interest or stake in the sale of this business and has not verified any of the information and assumes no responsibility for its accuracy, veracity, or completeness. See our full Terms of Use. Learn how to avoid scams.
